Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 12/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 10/20 | 0.41 |
| ▸ | HTR2B | P41595 | 10/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | HTR1A | P08908 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31021691 | 0.85 | HTR2A (0.48) | HTR2ASLC6A4KCNH2TAAR1HTR2C | |
| SCHEMBL3390630 | 0.84 | TAAR1 (0.48) | HTR2ASLC6A4KCNH2TAAR1HTR2C | |
| SCHEMBL15888289 | 0.82 | TAAR1 (0.52) | HTR2ATAAR1HTR2CHTR2BMAPT | |
| SCHEMBL11844278 | 0.82 | TAAR1 (0.47) | HTR2ATAAR1HTR2CHTR2BHTR1A | |
| SCHEMBL3775780 | 0.82 | HTR2A (0.41) | HTR2ASLC6A4KCNH2TAAR1HTR2C | |
| SCHEMBL5104667 | 0.81 | PDE4A (0.46) | HTR2ASLC6A4KCNH2TAAR1HTR2C | |
| SCHEMBL3227013 | 0.79 | HTR2A (0.46) | HTR2ATAAR1HTR2C | |
| SCHEMBL25219237 | 0.79 | HTR2A (0.43) | HTR2ATAAR1HTR2CHTR2BHTR1A | |
| SCHEMBL16068899 | 0.79 | TAAR1 (0.52) | HTR2ATAAR1HTR2CHTR2BMAPT | |
| SCHEMBL6738129 | 0.78 | TAAR1 (0.51) | HTR2ATAAR1HTR2CHTR2BMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8883786-B2 | Glucocorticoid receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2014-11-11 | — | — | US | disclosed |
| EP-2411361-B1 | 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2014-06-18 | — | — | EP | disclosed |
| US-20130045972-A1 | GLUCOCORTICOID RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-02-21 | — | — | US | disclosed |
| US-8143280-B2 | Glucocorticoid receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2012-03-27 | — | — | US | disclosed |
| US-8138189-B2 | Substituted benzene compounds as modulators of the glucocorticoid receptor | HOFFMAN-LA ROCHE INC. (US) | 2012-03-20 | — | — | US | disclosed |
| EP-2411361-A1 | 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2012-02-01 | — | — | EP | disclosed |
| EP-2205562-B1 | 1,1,1-TRIFLUORO-2-HYDROXY-3-PHENYLPROPANE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2011-03-16 | — | — | EP | disclosed |
| US-20100249139-A1 | 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS | HOFFMANN-LA ROCHE, INC. | 2010-09-30 | — | — | US | disclosed |
| WO-2010108902-A1 | 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-09-30 | — | — | WO | disclosed |
| EP-2205562-A1 | 1,1,1-TRIFLUORO-2-HYDROXY-3-PHENYLPROPANE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2010-07-14 | — | — | EP | disclosed |
| US-7442792-B2 | halogenation of pyrazolo[1,5-a][1,3,5]triazin-4-ol's, with phosphorus oxyhalides, then dehalogenation and amination to yield dimethylpyrazolo[1,5-a][1,3,5]triazin-4-amine's, used as corticotropin releasing factor (CRF) receptor antagonists; anxiolytic agents; antidepressants | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2008-10-28 | — | — | US | disclosed |
| US-20070161790-A1 | Process for the preparation of pyrazolo[1,5-a]-1,3,5-triazines and intermediates thereof | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2007-07-12 | — | — | US | disclosed |
| US-20070161790-A1 | Process for the preparation of pyrazolo[1,5-a]-1,3,5-triazines and intermediates thereof | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2007-07-12 | — | — | US | disclosed |
| US-20070161790-A1 | Process for the preparation of pyrazolo[1,5-a]-1,3,5-triazines and intermediates thereof | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2007-07-12 | — | — | US | disclosed |
| US-7208596-B2 | Processes for the preparation of pyrazolo[1,5-a]-1,3,5-triazines and intermediates thereof | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2007-04-24 | — | — | US | disclosed |
| US-7208596-B2 | Processes for the preparation of pyrazolo[1,5-a]-1,3,5-triazines and intermediates thereof | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2007-04-24 | — | — | US | disclosed |
| US-7208596-B2 | Processes for the preparation of pyrazolo[1,5-a]-1,3,5-triazines and intermediates thereof | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2007-04-24 | — | — | US | disclosed |
| EP-1706408-A2 | PROCESSES FOR THE PREPARATION OF PYRAZOLO[1,5- A] -1,3,5-TRIAZINES AND INTERMEDIATES THEREOF | Bristol-Myers Squibb Pharma Company (US) | 2006-10-04 | — | — | EP | disclosed |
| US-20050143380-A1 | Processes for the preparation of pyrazolo[1,5-a]-1,3,5-triazines and intermediates thereof | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2005-06-30 | — | — | US | disclosed |
| WO-2005051954-A2 | PROCESSES FOR THE PREPARATION OF PYRAZOLO[1,5-a]-1,3,5-TRIAZINES AND INTERMEDIATES THEREOF | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249139-A1 | 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS | NR3C1, NR3C2, CRHR1 | HTR2A 101/4885SLC6A4 525/4885KCNH2 2332/4885 |
| US-20070161790-A1 | Process for the preparation of pyrazolo[1,5-a]-1,3,5-triazines and intermediates thereof | CRHR1, CRH, CRHR2 | HTR2A 31/4885SLC6A4 796/4885KCNH2 3247/4885 |
| US-20130045972-A1 | GLUCOCORTICOID RECEPTOR ANTAGONISTS | NR3C1, NR3C2, MC2R | HTR2A 176/4885SLC6A4 784/4885KCNH2 1967/4885 |
| US-20050143380-A1 | Processes for the preparation of pyrazolo[1,5-a]-1,3,5-triazines and intermediates thereof | CRHR1, CRH, CRHR2 | HTR2A 37/4885SLC6A4 744/4885KCNH2 3321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.